Share on LinkedInShare on LinkedIn

ARTICLE · 22 DECEMBER 2014

Cipla Seems To Be On The Skids

Earlier in the month of November, Indian generic drug maker Cipla Ltd. had requested the Central government to revoke five patents held by Swiss firm Novartis AG on respiratory drug Indacetorol, used for the treatment of Chronic Obstructive Pulmonary Disease (COPD) under the brand name ‘ONBREZ’.

IndiaIntellectual Property

Earlier in the month of November, Indian generic drug maker Cipla Ltd. had requested the Central government to revoke five patents held by Swiss firm Novartis AG on respiratory drug Indacetorol, used for the treatment of Chronic Obstructive Pulmonary Disease (COPD) under the brand name 'ONBREZ'. Cipla had filed a representation before the Department of Industrial Policy & Promotion (DIPP) to cancel the patents on the ground that the Swiss company had held them for six years without making the medicine locally or importing it in the quantity which is required.

The representation was filed under section 66 and section 92 of the Indian Patents Act, 1970.

Section 66 empowers Central Government to revoke a patent on the grounds of it being mischievous to the State or prejudicial to the public. The power given to the Government of India under section 66 of the Indian Patents Act has been exercised only twice so far. The first was when a process patent had been granted to

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from